MEDI0457 + Durvalumab
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Conditions
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
Trial Timeline
Sep 17, 2019 → Mar 25, 2021
NCT ID
NCT04001413About MEDI0457 + Durvalumab
MEDI0457 + Durvalumab is a phase 2 stage product being developed by AstraZeneca for HPV Positive Oropharyngeal Squamous Cell Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04001413. Target conditions include HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04001413 | Phase 2 | Withdrawn |
Competing Products
20 competing products in HPV Positive Oropharyngeal Squamous Cell Carcinoma